{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T18:37:02Z","timestamp":1769452622547,"version":"3.49.0"},"reference-count":259,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006595","name":"UEFISCDI","doi-asserted-by":"publisher","award":["PN-III-P4-ID-PCE-2020-1649"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1649"]}],"id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Adult astrocytomas, particularly IDH1\/IDH2-wildtype infiltrating astrocytic gliomas, represent a significant challenge for medical professionals. Despite recent progress in understanding tumor biology and the use of molecular biomarkers, therapeutic options have not significantly improved patient outcomes. Although targeted therapies, such as small-molecule tyrosine kinase inhibitors (TKIs), have shown benefits in other solid tumors, they have largely failed to improve survival in adult astrocytoma patients. Characterized by remarkable heterogeneity, these tumors develop robust drug resistance mechanisms. The molecular processes driving this resistance are complex and not yet fully understood. In this review, we briefly present the growth factor receptors (GFRs) and their signaling pathways in adult astrocytomas and discuss the known mechanisms of resistance to small-molecule tyrosine kinase inhibitors.<\/jats:p>","DOI":"10.3390\/ijms27031196","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:14:23Z","timestamp":1769415263000},"page":"1196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3362-7382","authenticated-orcid":false,"given":"Roxana","family":"Radu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020022 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anica","family":"Dricu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020022 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-5833","authenticated-orcid":false,"given":"Ligia Gabriela","family":"Tataranu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020022 Bucharest, Romania"},{"name":"Department of Neurosurgery, Clinical Emergency Hospital \u201cBagdasar-Arseni\u201d, 041915 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-5378","authenticated-orcid":false,"given":"Oana","family":"Alexandru","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Medicine and Pharmacy, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yoda, R.A., and Cimino, P.J. (2023). Classification and Grading of Central Nervous System Tumors According to the World Health Organization, Thieme Medical Publishers, Inc.. [5th ed.]. Seminars in Neurology, 2023.","DOI":"10.1055\/s-0043-1776793"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-oncology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Huang, B., Zhao, H., Yang, J., Liu, F., Caruso, G., Zhang, H., and Chen, L. (2025). Editorial: Clinical therapy of brain tumors. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1610463"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-015-1993-9","article-title":"Presurgical navigated TMS motor cortex mapping improves outcome in glioblastoma surgery: A controlled observational study","volume":"126","author":"Picht","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179\u2013193; discussion 193\u2013194","DOI":"10.1227\/00006123-199508000-00001","article-title":"The role of growth factor receptors in central nervous system development and neoplasia","volume":"37","author":"Weiner","year":"1995","journal-title":"Neurosurgery"},{"key":"ref_6","first-page":"1101","article-title":"Molecular targeting for malignant gliomas (Review)","volume":"24","author":"Kondo","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-024-06547-3","article-title":"mTOR pathway occupies a central role in the emergence of latent cancer cells","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"He, S., Li, Q., Huang, Q., and Cheng, J. (2022). Targeting protein kinase C for cancer therapy. Cancers, 14.","DOI":"10.3390\/cancers14051104"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1476-4598-9-75","article-title":"Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy","volume":"9","author":"Sierra","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: Targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Fabro, F., Lamfers, M.L., and Leenstra, S. (2022). Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14030600"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111420","DOI":"10.1016\/j.celrep.2022.111420","article-title":"Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma","volume":"40","author":"Qazi","year":"2022","journal-title":"Cell Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.celrep.2016.11.056","article-title":"Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition","volume":"17","author":"Segerman","year":"2016","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1158\/0008-5472.CAN-10-2353","article-title":"Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis","volume":"70","author":"Mazzoleni","year":"2010","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2174\/138161211797249260","article-title":"Glioma stem cell maintenance: The role of the microenvironment","volume":"17","author":"Hitomi","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/neuonc\/noab302","article-title":"Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors","volume":"24","author":"Knudsen","year":"2022","journal-title":"Neuro-oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2174\/0109298673281283240101053940","article-title":"Analysis of clinical success and molecular mechanisms of action of novel anti-glioblastoma drugs: A review","volume":"32","author":"Abdullaeva","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s40478-019-0803-6","article-title":"Immune landscapes associated with different glioblastoma molecular subtypes","volume":"7","author":"Lynch","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_25","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","article-title":"HIF transcription factors, inflammation, and immunity","volume":"41","author":"Palazon","year":"2014","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-0620-8_3","article-title":"Hypoxia in tumors: Pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications","volume":"812","author":"Vaupel","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"vdad009","DOI":"10.1093\/noajnl\/vdad009","article-title":"Tumor microenvironment in glioblastoma: Current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","article-title":"BDDCS, the Rule of 5 and drugability","volume":"101","author":"Benet","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mo, F., Pellerino, A., Soffietti, R., and Rud\u00e0, R. (2021). Blood\u2013brain barrier in brain tumors: Biology and clinical relevance. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312654"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0000000000000814","article-title":"Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes","volume":"83","author":"Boisselier","year":"2014","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1125951","article-title":"Targeting tyrosine kinases in cancer: The second wave","volume":"312","author":"Baselga","year":"2006","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cbi.2015.08.009","article-title":"Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents","volume":"240","author":"Joshi","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eaaz4125","DOI":"10.1126\/sciadv.aaz4125","article-title":"Phenotype stability under dynamic brain-tumor environment stimuli maps glioblastoma progression in patients","volume":"6","author":"Rajapakse","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_37","first-page":"1740763","article-title":"Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells","volume":"2019","author":"Mansouri","year":"2019","journal-title":"J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190802312844","article-title":"EGFR family: Structure physiology signalling and therapeutic targets","volume":"26","author":"Burgess","year":"2008","journal-title":"Growth Factors"},{"key":"ref_39","first-page":"55","article-title":"Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches","volume":"24","author":"Alexandru","year":"2020","journal-title":"Contemp. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: Recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1593\/neo.10688","article-title":"Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance","volume":"12","author":"Hatanpaa","year":"2010","journal-title":"Neoplasia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2013.09.004","article-title":"EGFR phosphorylates tumor-derived EGFRvIII driving STAT3\/5 and progression in glioblastoma","volume":"24","author":"Fan","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00401-025-02928-w","article-title":"EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma","volume":"150","author":"Slocum","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","article-title":"Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas","volume":"108","author":"Andersson","year":"2004","journal-title":"Acta Neuropathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1074\/jbc.M807111200","article-title":"Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors","volume":"284","author":"Griffero","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","article-title":"Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells","volume":"38","author":"Vengoji","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00232-022-00274-6","article-title":"Predicting blood\u2013brain barrier permeation of Erlotinib and JCN037 by Molecular Simulation","volume":"256","author":"Liang","year":"2023","journal-title":"J. Membr. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.111.190488","article-title":"Brain distribution of cediranib is limited by active efflux at the blood-brain barrier","volume":"341","author":"Wang","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2012.05.028","article-title":"Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp1\/Abcg2) mediated efflux with m-TOR inhibitors","volume":"434","author":"Minocha","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dang, Y., Zhao, Z., Wang, B., Du, A., Li, S., Yuan, G., and Pan, Y. (2025). Polymeric Polylactic Acid\u2013Glycolic Acid-Based Nanoparticles Deliver Nintedanib Across the Blood\u2013Brain Barrier to Inhibit Glioblastoma Growth. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020443"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood\u2013brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"P02","DOI":"10.1158\/1535-7163.TARG-21-P02-04","article-title":"BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases","volume":"20","author":"Lucas","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wen, P., Ahluwalia, M., Odia, Y., Mckean, M., Snyder, J., Colman, H., Lobbous, M., Nghiemphu, L., Chong, R., and Yang, J. (2025, December 23). A Phase 1 Study of ERAS-801, a Potent, Selective, and Central Nervous System (CNS)-Penetrant Epidermal Growth Factor Receptor (EGFR) Inhibitor, for Patients with Recurrent Glioblastoma Multiforme (GBM). Available online: https:\/\/scholarlycommons.henryford.com\/neurosurgery_mtgabstracts\/159\/.","DOI":"10.1093\/neuonc\/noae165.0415"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074","volume":"80","author":"Uhm","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/nos265","article-title":"A phase I\/II trial of vandetanib for patients with recurrent malignant glioma","volume":"14","author":"Kreisl","year":"2012","journal-title":"Neuro-oncology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-012-1009-y","article-title":"Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme","volume":"111","author":"Muhic","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/MCB.21.17.5899-5912.2001","article-title":"Growth factors can influence cell growth and survival through effects on glucose metabolism","volume":"21","author":"Plas","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1200\/JCO.2024.42.16_suppl.2068","article-title":"Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results","volume":"42","author":"Wen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-009-0008-0","article-title":"Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme","volume":"97","author":"Holdhoff","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_67","first-page":"567","article-title":"Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-\u03b2 tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"19","author":"Batchelor","year":"2017","journal-title":"Neuro-oncology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","article-title":"Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study","volume":"26","author":"Raymond","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27378","DOI":"10.1038\/srep27378","article-title":"Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling","volume":"6","author":"Frolov","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/cns-2015-0010","article-title":"A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma","volume":"5","author":"Odia","year":"2016","journal-title":"CNS Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2012.05.038","article-title":"Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib","volume":"436","author":"Minocha","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"142861","DOI":"10.1016\/j.ijbiomac.2025.142861","article-title":"Nose-to-brain delivery of sorafenib-loaded lipid-based poloxamer-carrageenan nanoemulgel: Formulation and therapeutic investigation in glioblastoma-induced orthotopic rat model","volume":"309","author":"Khot","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.113.208959","article-title":"Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain","volume":"347","author":"Oberoi","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","article-title":"Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Neuro-oncology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"vdaa124","DOI":"10.1093\/noajnl\/vdaa124","article-title":"Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","volume":"2","author":"Chen","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-010-0402-7","article-title":"Phase II study of sunitinib malate in patients with recurrent high-grade glioma","volume":"103","author":"Neyns","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1538-7445.AM2022-6296","article-title":"Preclinical evaluation of a panel of FGFR inhibitors for their normal brain and brain tumor distribution","volume":"82","author":"Knight","year":"2022","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"vi20","DOI":"10.1093\/neuonc\/noz175.076","article-title":"Actr-33. Infigratinib (Bgj398) in Patients with Recurrent Gliomas with Fibroblast Growth Factor Receptor (Fgfr) Alterations: A Multicenter Phase Ii Study","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro-oncology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/35067005","article-title":"Tie receptors: New modulators of angiogenic and lymphangiogenic responses","volume":"2","author":"Jones","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-14-1105","article-title":"Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/neuonc\/now030","article-title":"Novel MET\/TIE2\/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models","volume":"18","author":"Piao","year":"2016","journal-title":"Neuro-oncology"},{"key":"ref_83","first-page":"112","article-title":"XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC","volume":"13","author":"Zhang","year":"2010","journal-title":"IDrugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/neuonc\/nox154","article-title":"Phase II study of cabozantinib in patients with progressive glioblastoma: Subset analysis of patients naive to antiangiogenic therapy","volume":"20","author":"Wen","year":"2018","journal-title":"Neuro-oncology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1538-7445.AM2014-3714","article-title":"Trametinib (Mekinist TM) has limited brain distribution in the mouse model","volume":"74","author":"Vaidhyanathan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-016-2158-1","article-title":"Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats","volume":"129","author":"Netland","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/neuonc\/nop058","article-title":"Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma","volume":"12","author":"Koul","year":"2010","journal-title":"Neuro-oncology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1538-7445.AM2015-4514","article-title":"PQR309: A potent, brain-penetrant, dual pan-PI3K\/mTOR inhibitor with excellent oral bioavailability and tolerability","volume":"75","author":"Cmiljanovic","year":"2015","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in Patients with Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial","volume":"37","author":"Wen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_92","first-page":"1270","article-title":"Phase II study of PX-866 in recurrent glioblastoma","volume":"17","author":"Pitz","year":"2015","journal-title":"Neuro-oncology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1200\/JCO.2022.40.16_suppl.2047","article-title":"Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results","volume":"40","author":"Wen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/np800049y","article-title":"Potent inhibition of human phosphodiesterase-5 by icariin derivatives","volume":"71","author":"Galli","year":"2008","journal-title":"J. Nat. Prod."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","article-title":"Oral bioavailability of curcumin: Problems and advancements","volume":"24","author":"Liu","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_96","first-page":"4628","article-title":"Icaritin induces apoptotic and autophagic cell death in human glioblastoma cells","volume":"8","author":"Li","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/01635581.2016.1187281","article-title":"Intratumoral concentrations and effects of orally administered micellar curcuminoids in glioblastoma patients","volume":"68","author":"Schiborr","year":"2016","journal-title":"Nutr. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"RTOG 0211: A phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-014-1631-y","article-title":"Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas","volume":"121","author":"Norden","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"ref_100","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro-oncology"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"de S\u00e3o Jos\u00e9, V.S., Vieira, B.M., Neto, V.M., and Lima, L.M. (2024). Repurposing Osimertinib and Gedatolisib for Glioblastoma Treatment: Evidence of Synergistic Effects in an In Vitro Phenotypic Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121623"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/1568009616666161215162515","article-title":"The role of EGFR-met interactions in the pathogenesis of glioblastoma and resistance to treatment","volume":"17","author":"Guo","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_103","first-page":"1477","article-title":"Insulin-like growth factor 1\/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K\/AKT pathway in glioblastoma cells","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1016\/j.celrep.2020.02.014","article-title":"Glioblastoma cell resistance to EGFR and MET inhibition can be overcome via blockade of FGFR-SPRY2 bypass signaling","volume":"30","author":"Day","year":"2020","journal-title":"Cell Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/01.WNL.0000158654.07080.B0","article-title":"EGFR tyrosine kinase domain mutations in human gliomas","volume":"64","author":"Marie","year":"2005","journal-title":"Neurology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","article-title":"A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation","volume":"65","author":"Thiessen","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"110374","DOI":"10.1016\/j.jbc.2025.110374","article-title":"Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations","volume":"301","author":"Watson","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.1114033109","article-title":"Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response","volume":"109","author":"Szerlip","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/2159-8290.CD-12-0502","article-title":"De-repression of PDGFR\u03b2 transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients","volume":"3","author":"Akhavan","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0959-8049(22)00864-4","article-title":"Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models","volume":"174","author":"Lucas","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27012","DOI":"10.1038\/srep27012","article-title":"IGF1R as a key target in high risk, metastatic medulloblastoma","volume":"6","author":"Svalina","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/bjc.2015.242","article-title":"IGF-IR: A new prognostic biomarker for human glioblastoma","volume":"113","author":"Maris","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/neuonc\/nou344","article-title":"Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms","volume":"17","author":"Zamykal","year":"2015","journal-title":"Neuro-oncology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41416-019-0677-1","article-title":"Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma","volume":"122","author":"Simpson","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Martin, A., Fernandez, M.C., Cattaneo, E.R., Schuster, C.D., Venara, M., Cl\u00e9ment, F., Berenstein, A., Lombardi, M.G., Bergad\u00e1, I., and Gutierrez, M. (2022). Type 1 insulin-like growth factor receptor nuclear localization in high-grade glioma cells enhances motility, metabolism, and in vivo tumorigenesis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.849279"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-007-9417-0","article-title":"Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells","volume":"85","author":"Carapancea","year":"2007","journal-title":"J. Neuro-Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-008-9753-8","article-title":"Growth factor receptors signaling in glioblastoma cells: Therapeutic implications","volume":"92","author":"Carapancea","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Fuentes-Baile, M., Ventero, M.P., Encinar, J.A., Garc\u00eda-Morales, P., Poveda-Deltell, M., P\u00e9rez-Valenciano, E., Barber\u00e1, V.M., Gallego-Plazas, J., Rodr\u00edguez-Lescure, \u00c1., and Mart\u00edn-Nieto, J. (2020). Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines. Cancers, 12.","DOI":"10.3390\/cancers12123717"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","article-title":"BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR","volume":"8","author":"Carboni","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-08-2980","article-title":"Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor\/HER3\/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma","volume":"15","author":"Baron","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1038\/onc.2010.640","article-title":"Efficacy of and resistance to anti-IGF-1R therapies in Ewing\u2019s sarcoma is dependent on insulin receptor signaling","volume":"30","author":"Garofalo","year":"2011","journal-title":"Oncogene"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"E1016","DOI":"10.1073\/pnas.1520245113","article-title":"Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation","volume":"113","author":"Triplett","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-15-1677","article-title":"InsR\/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma","volume":"22","author":"Ma","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bbrc.2004.06.175","article-title":"Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis","volume":"321","author":"Steinbach","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1535-7163.MCT-16-0616","article-title":"Insulin-mediated signaling facilitates resistance to PDGFR inhibition in proneural hPDGFB-driven gliomas","volume":"16","author":"Ran","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1155\/2007\/926274","article-title":"Molecular alterations of KIT oncogene in gliomas","volume":"29","author":"Gomes","year":"2007","journal-title":"Anal. Cell. Pathol."},{"key":"ref_129","first-page":"555","article-title":"Abundance of Flt3 and its ligand in astrocytic tumors","volume":"6","author":"Andrae","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061\u20131068. Erratum in Nature 2013, 494, 506.","DOI":"10.1038\/nature07385"},{"key":"ref_131","first-page":"3213","article-title":"Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops","volume":"52","author":"Hermanson","year":"1992","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.gene.2012.01.065","article-title":"A subset of human gliomas shows over-expression of KIT without its amplification","volume":"497","author":"Saini","year":"2012","journal-title":"Gene"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Alexandru, O., Sevastre, A.-S., Castro, J., Artene, S.-A., Tache, D.E., Purcaru, O.S., Sfredel, V., Tataranu, L.G., and Dricu, A. (2019). Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194663"},{"key":"ref_134","first-page":"e88055","article-title":"Improving the Response of High-Grade Glioma (HGG) Cells to Temozolomide Treatment Through Combination with Imatinib","volume":"17","author":"Staicu","year":"2025","journal-title":"Cureus"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4161\/cbt.4.11.2253","article-title":"Activating mutations in c-KIT and PDGFR\u03b1 are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_136","first-page":"792","article-title":"ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells","volume":"8","author":"Song","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00005072-199906000-00006","article-title":"Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain","volume":"58","author":"Proescholdt","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42047-020-00060-5","article-title":"The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas","volume":"3","author":"Loureiro","year":"2020","journal-title":"Surg. Exp. Pathol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"31050","DOI":"10.18632\/oncotarget.2910","article-title":"Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma","volume":"6","author":"Kessler","year":"2015","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): A randomised controlled phase 2 EORTC trial","volume":"19","author":"Klein","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Zou","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neulet.2010.05.009","article-title":"Sorafenib exerts anti-glioma activity in vitro and in vivo","volume":"478","author":"Siegelin","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.47162\/RJME.64.2.07","article-title":"In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology","volume":"64","author":"Dobrescu","year":"2023","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2092-2","article-title":"Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma","volume":"128","author":"Duerinck","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s44178-024-00081-0","article-title":"Antiangiogenic therapy: How far is it to upgrade?","volume":"3","author":"Wang","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Mossahebi-Mohammadi, M., Quan, M., Zhang, J.-S., and Li, X. (2020). FGF signaling pathway: A key regulator of stem cell pluripotency. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00079"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.1038\/ncomms10262","article-title":"Mechanism of FGF receptor dimerization and activation","volume":"7","author":"Sarabipour","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Jimenez-Pascual, A., and Siebzehnrubl, F.A. (2019). Fibroblast growth factor receptor functions in glioblastoma. Cells, 8.","DOI":"10.3390\/cells8070715"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: Cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.ATV.20.12.2573","article-title":"Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization","volume":"20","author":"Chae","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.18632\/oncotarget.204","article-title":"Tie2\/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype","volume":"1","author":"Liu","year":"2010","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/0008-5472.CAN-05-1149","article-title":"Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the \u03b1v\u03b21 integrin and focal adhesion kinase signaling pathway","volume":"66","author":"Hu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: Principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"9173","DOI":"10.1038\/sj.onc.1208146","article-title":"Regulation of c-Met-dependent gene expression by PTEN","volume":"23","author":"Abounader","year":"2004","journal-title":"Oncogene"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Cruickshanks, N., Zhang, Y., Yuan, F., Pahuski, M., Gibert, M., and Abounader, R. (2017). Role and therapeutic targeting of the HGF\/MET pathway in glioblastoma. Cancers, 9.","DOI":"10.3390\/cancers9070087"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/1078-0432.CCR-18-0926","article-title":"Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma","volume":"25","author":"Cruickshanks","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia (08876924)"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Martin-Vega, A., and Cobb, M.H. (2023). Navigating the ERK1\/2 MAPK cascade. Biomolecules, 13.","DOI":"10.3390\/biom13101555"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"17933","DOI":"10.1073\/pnas.1317026110","article-title":"Evolutionary etiology of high-grade astrocytomas","volume":"110","author":"Song","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bpa.12709","article-title":"Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas","volume":"29","author":"Schittenhelm","year":"2019","journal-title":"Brain Pathol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/sj.onc.1201455","article-title":"Proliferation of human malignant astrocytomas is dependent on Ras activation","volume":"15","author":"Guha","year":"1997","journal-title":"Oncogene"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1083\/jcb.143.5.1375","article-title":"Tumor suppressor PTEN inhibits integrin-and growth factor\u2013mediated mitogen-activated protein (MAP) kinase signaling pathways","volume":"143","author":"Gu","year":"1998","journal-title":"J. Cell Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1083\/jcb.146.2.389","article-title":"Shc and FAK differentially regulate cell motility and directionality modulated by PTEN","volume":"146","author":"Gu","year":"1999","journal-title":"J. Cell Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e64846","DOI":"10.7554\/eLife.64846","article-title":"NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1","volume":"10","author":"Marques","year":"2021","journal-title":"eLife"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro-oncology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: A Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro-oncology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1158\/1078-0432.CCR-21-2660","article-title":"Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAFV600E-mutant human glioma","volume":"27","author":"Schreck","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"561","DOI":"10.15252\/embj.201593564","article-title":"Phosphatidylinositol 3-phosphates\u2014At the interface between cell signalling and membrane traffic","volume":"35","author":"Marat","year":"2016","journal-title":"EMBO J."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ijc.10909","article-title":"Dysregulated PTEN-PKB and negative receptor status in human breast cancer","volume":"104","author":"Shi","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: Navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41389-017-0004-8","article-title":"The effects of PI3K-mediated signalling on glioblastoma cell behaviour","volume":"6","author":"Langhans","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"20956","DOI":"10.1038\/s41598-023-47892-1","article-title":"FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2","volume":"13","author":"Tsutsumi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2021.11.061","article-title":"TRAM2 promotes the malignant progression of glioma through PI3K\/AKT\/mTOR pathway","volume":"586","author":"Gao","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1111\/jcmm.15107","article-title":"RIOK2 is negatively regulated by miR-4744 and promotes glioma cell migration\/invasion through epithelial-mesenchymal transition","volume":"24","author":"Song","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Singh, S., Barik, D., Lawrie, K., Mohapatra, I., Prasad, S., Naqvi, A.R., Singh, A., and Singh, G. (2023). Unveiling novel avenues in mTOR-targeted therapeutics: Advancements in glioblastoma treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914960"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: Targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"110350","DOI":"10.1016\/j.cellsig.2022.110350","article-title":"Crosstalk between PI3K\/AKT\/mTOR and WNT\/\u03b2-Catenin signaling in GBM-Could combination therapy checkmate the collusion?","volume":"95","author":"Precilla","year":"2022","journal-title":"Cell. Signal."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Larsen, L.J., and M\u00f8ller, L.B. (2020). Crosstalk of hedgehog and mTORC1 pathways. Cells, 9.","DOI":"10.3390\/cells9102316"},{"key":"ref_188","first-page":"2419","article-title":"Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase","volume":"54","author":"Powis","year":"1994","journal-title":"Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1750-3639.2003.tb00481.x","article-title":"Genetic alterations and aberrant expression of genes related to the phosphatidyl-lnositol-3\u2032-kinase\/protein kinase B (Akt) signal transduction pathway in glioblastomas","volume":"13","author":"Knobbe","year":"2003","journal-title":"Brain Pathol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-019-0720-8","article-title":"PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma","volume":"7","author":"Tanaka","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: Effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist. Updates"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1566524013666131203103147","article-title":"miR-221\/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status","volume":"14","author":"Li","year":"2014","journal-title":"Curr. Mol. Med."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Chuang, H.-Y., Hsu, L.-Y., Pan, C.-M., Pikatan, N.W., Yadav, V.K., Fong, I.-H., Chen, C.-H., Yeh, C.-T., and Chiu, S.-C. (2021). The e3 ubiquitin ligase nedd4-1 mediates temozolomide-resistant glioblastoma through pten attenuation and redox imbalance in nrf2\u2013ho-1 axis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910247"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jnci\/dji161","article-title":"Epidermal growth factor receptor, protein kinase B\/Akt, and glioma response to erlotinib","volume":"97","author":"Prados","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","article-title":"Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition","volume":"4","author":"Goudar","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.biopha.2016.04.006","article-title":"Tangeretin induces cell cycle arrest and apoptosis through upregulation of PTEN expression in glioma cells","volume":"81","author":"Ma","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"108412","DOI":"10.1016\/j.abb.2020.108412","article-title":"Curcumin suppresses glioblastoma cell proliferation by p-AKT\/mTOR pathway and increases the PTEN expression","volume":"689","author":"Wang","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_201","first-page":"1263","article-title":"The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines","volume":"35","author":"Elhag","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/ol.2016.4113","article-title":"Epithelial-mesenchymal transition in glioblastoma progression","volume":"11","author":"Iwadate","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13046-020-01641-8","article-title":"Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma","volume":"39","author":"Liu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"41947","DOI":"10.18632\/oncotarget.16710","article-title":"Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K\/Akt signaling in glioma","volume":"8","author":"Song","year":"2017","journal-title":"Oncotarget"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10409238.2018.1442408","article-title":"Protein kinase C: Perfectly balanced","volume":"53","author":"Newton","year":"2018","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: How does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrc2110","article-title":"Protein kinase C and other diacylglycerol effectors in cancer","volume":"7","author":"Griner","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4161\/cbt.23615","article-title":"PKC signaling in glioblastoma","volume":"14","author":"Carmo","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/0008-5472.CAN-18-2808","article-title":"Cooperative blockade of PKC\u03b1 and JAK2 drives apoptosis in glioblastoma","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Masliantsev, K., Karayan-Tapon, L., and Guichet, P.-O. (2021). Hippo signaling pathway in gliomas. Cells, 10.","DOI":"10.3390\/cells10010184"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/cas.14408","article-title":"Tumor-associated macrophage interleukin-\u03b2 promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells","volume":"111","author":"Lu","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1158\/0008-5472.CAN-05-1064","article-title":"Protein kinase C-\u03b5 regulates the apoptosis and survival of glioma cells","volume":"65","author":"Okhrimenko","year":"2005","journal-title":"Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1038\/sj.onc.1204899","article-title":"Differential activation of ERKs to focal adhesions by PKC \u03b5 is required for PMA-induced adhesion and migration of human glioma cells","volume":"20","author":"Besson","year":"2001","journal-title":"Oncogene"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1038\/sj.onc.1208093","article-title":"PKC-\u03b7 mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways","volume":"23","author":"Aeder","year":"2004","journal-title":"Oncogene"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bbamcr.2011.03.007","article-title":"PKC-\u03b9 promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway","volume":"1813","author":"Desai","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"109819","DOI":"10.1016\/j.cellsig.2020.109819","article-title":"The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma","volume":"77","author":"Dey","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1528-1157.1995.tb00494.x","article-title":"High-dose tamoxifen in treatment of brain tumors: Interaction with antiepileptic drugs","volume":"36","author":"Rabinowicz","year":"1995","journal-title":"Epilepsia"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.1999.17.2.645","article-title":"Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study","volume":"17","author":"Brandes","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijrobp.2010.12.053","article-title":"Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma","volume":"82","author":"Patel","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/neuonc\/nop042","article-title":"A phase I\/II trial of enzastaurin in patients with recurrent high-grade gliomas","volume":"12","author":"Kreisl","year":"2010","journal-title":"Neuro-oncology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/neuonc\/nop070","article-title":"Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study","volume":"12","author":"Butowski","year":"2010","journal-title":"Neuro-oncology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.18632\/oncotarget.3208","article-title":"High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma","volume":"6","author":"Meng","year":"2014","journal-title":"Oncotarget"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3171\/2015.11.JNS15432","article-title":"Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma","volume":"126","author":"Cheng","year":"2017","journal-title":"J. Neurosurg."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"19750","DOI":"10.1002\/jcp.28575","article-title":"The interplay between glioblastoma and microglia cells leads to endothelial cell monolayer dysfunction via the interleukin-6-induced JAK2\/STAT3 pathway","volume":"234","author":"Couto","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccr.2013.09.017","article-title":"EGFR and EGFRvIII in glioblastoma: Partners in crime","volume":"24","author":"Zadeh","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00401-011-0832-0","article-title":"SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation","volume":"122","author":"Lindemann","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1111\/bph.13986","article-title":"Rubiarbonone C inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr705 signalling pathways","volume":"174","author":"Park","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-018-0618-0","article-title":"miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3\/Bcl2 signaling pathway","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/OTT.S237841","article-title":"B7-H3 regulates glioma growth and cell invasion through a JAK2\/STAT3\/Slug-dependent signaling pathway","volume":"13","author":"Zhong","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-14-0834","article-title":"Antiangiogenic therapy for glioblastoma: Current status and future prospects","volume":"20","author":"Batchelor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Abbas, M., Ullah, M.F., Aziz, M.H., Beylerli, O., Alam, M.A., Syed, M.A., Uddin, S., and Ahmad, A. (2022). Long Non-Coding RNAs Regulated NF-\u03baB Signaling in Cancer Metastasis: Micromanaging by Not so Small Non-Coding RNAs, Elsevier. Seminars in cancer biology, 2022.","DOI":"10.1016\/j.semcancer.2021.07.015"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: Mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling","volume":"132","author":"Ms","year":"2008","journal-title":"Cell"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ncb2621","article-title":"Telomerase directly regulates NF-\u03baB-dependent transcription","volume":"14","author":"Ghosh","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1007\/s00018-021-03906-7","article-title":"The multifaceted NF-kB: Are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?","volume":"78","author":"Medeiros","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.molcel.2012.09.028","article-title":"EGFR-induced and PKC\u03b5 monoubiquitylation-dependent NF-\u03baB activation upregulates PKM2 expression and promotes tumorigenesis","volume":"48","author":"Yang","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11010-007-9593-4","article-title":"NF-\u03baB controls growth of glioblastomas\/astrocytomas","volume":"307","author":"Smith","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature08712","article-title":"The transcriptional network for mesenchymal transformation of brain tumours","volume":"463","author":"Carro","year":"2010","journal-title":"Nature"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study","volume":"14","author":"Friday","year":"2011","journal-title":"Neuro-oncology"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cncr.20776","article-title":"Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma","volume":"103","author":"Reardon","year":"2005","journal-title":"Cancer"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","article-title":"Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults","volume":"9","author":"Kesari","year":"2007","journal-title":"Neuro-oncology"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: New insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1471-4159.2007.04633.x","article-title":"Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF\u03baB transcription factors","volume":"102","author":"Dhandapani","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/ijo.2015.3271","article-title":"Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-\u03baB-dependent pathway downregulating MGMT expression","volume":"48","author":"Lan","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_249","first-page":"2050","article-title":"Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-\u03baB-dependent pathway","volume":"27","author":"Huang","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"210289","DOI":"10.1098\/rsob.210289","article-title":"Molecular mechanisms of developmental pathways in neurological disorders: A pharmacological and therapeutic review","volume":"12","author":"Jha","year":"2022","journal-title":"Open Biol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12964-018-0220-7","article-title":"A highlight on Sonic hedgehog pathway","volume":"16","author":"Carballo","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"ref_252","first-page":"1164","article-title":"Fms related tyrosine kinase 1 (Flt1) functions as an oncogene and regulates glioblastoma cell metastasis by regulating sonic hedgehog signaling","volume":"7","author":"Jiang","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"JING, F.-M. (2012). Sonic hedgehog signaling pathway in tumorigenesis of glioma. Acad. J. Second Mil. Med. Univ., 553\u2013557.","DOI":"10.3724\/SP.J.1008.2012.00553"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"18662","DOI":"10.1074\/jbc.M115.662882","article-title":"Forkhead box M1 is essential for nuclear localization of glioma-associated oncogene homolog 1 in glioblastoma multiforme cells by promoting importin-7 expression","volume":"290","author":"Xue","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12943-015-0396-z","article-title":"Significance of filamin A in mTORC2 function in glioblastoma","volume":"14","author":"Chantaravisoot","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Latour, M., Her, N.-G., Kesari, S., and Nurmemmedov, E. (2021). WNT signaling as a therapeutic target for glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168428"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1158\/0008-5472.CAN-04-1890","article-title":"Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation","volume":"65","author":"Purow","year":"2005","journal-title":"Cancer Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/nm.3328","article-title":"Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: New therapeutic opportunities","volume":"19","author":"Dabral","year":"2013","journal-title":"Nat. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/onc.2009.208","article-title":"Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival","volume":"28","author":"Sarangi","year":"2009","journal-title":"Oncogene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:17:43Z","timestamp":1769415463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":259,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031196"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031196","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}